Patterns of protease production during prostate cancer progression: Proteomic evidence for cascades in a transgenic model

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 4, 2003, Pages 272-280

  Bok, R A ^a   Hansell, E J ^b   Nguyen, T P ^a   Greenberg, N M ^c   McKerrow, J H ^b   Shuman, M A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Extracellur transgenic proteomics; Prostate cancer; Proteases

Indexed keywords

CYSTEINE PROTEINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; SERINE PROTEINASE; STROMELYSIN; UROKINASE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; LYMPH NODE; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; TRANSGENIC MOUSE; ZYMOGRAPHY;

ANIMALS; COLLAGENASES; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOPEPTIDASES; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; PROSTATE; PROSTATIC NEOPLASMS; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 0346007957     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500676     Document Type: Article

References (22)

1. Kim SJ et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998; 4: 177-182.
2. Powell WC et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993; 53: 417-422.
3. Shalinsky DR et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 1999; 878: 236-270.
4. Van Veldhuizen PJ, Sadasivan R, Cherian R, Wyatt A. Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 1996; 312: 8-11.
5. Bubley GJ et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
6. Doherty A et al. Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: implications for paracrine growth. J Pathol 1999; 188: 278-281.
7. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998; 35: 275-368.
8. Lin B et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59: 4180-4184.
9. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999; 96: 11054-11061.
10. Miyake H et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999; 39: 123-129.
11. Crowley CW et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5025.
12. Wan XS et al. Treatment with soybean-derived Bowman Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude mice. Prostate 1999; 41: 243-252.
13. Shepherd FA et al. Randomized double-blind pacebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC study. Am Soc Clin Oncol 2001; 20: 4a.
14. Greenberg NM et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-3443.
15. Takeuchi T et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-26342.
16. Furuya M et al. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography. Hum Pathol 2001; 32: 163-168.
17. Kristensen P, Eriksen J, Blasi F, Dano K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 1991; 115: 1763-1771.
18. Unkeless JC et al. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J Exp Med 1973; 137: 85-111.
19. Gururajan R, Grenet J, Lahti JM, Kidd VJ. Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. Genomics 1998; 52: 101-106.
20. Sternlicht MD et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98: 137-146.
21. Upadhyay J et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999; 5: 4105-4110.
22. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999; 11: 614-621.